{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T02:22:27Z","timestamp":1790907747452,"version":"4.1.0"},"reference-count":52,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2008,7,10]],"date-time":"2008-07-10T00:00:00Z","timestamp":1215648000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancer"],"published-print":{"date-parts":[[2008,8,15]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>BACKGROUND.<\/jats:title><jats:p>Ovarian tumors frequently express c\u2010Kit and\/or platelet\u2010derived growth factor receptors (PDGFRs). Imatinib mesylate blocks the growth of ovarian cancer cells in vitro and may enhance the activity of chemotherapy. This study was conducted to determine the activity of imatinib in combination with docetaxel in patients with recurrent, platinum\u2010resistant epithelial ovarian cancer (EOC).<\/jats:p><\/jats:sec><jats:sec><jats:title>METHODS.<\/jats:title><jats:p>Eligible patients had recurrent, platinum\u2010resistant, or refractory EOC that expressed PDGFR\u03b1 or c\u2010kit, as determined by immunohistochemistry. Imatinib mesylate at a dose of 600 mg orally once daily was administered continuously with docetaxel at a dose of 30 mg\/m<jats:sup>2<\/jats:sup> given intravenously once weekly in Weeks 1 through 4 of every 6\u2010week cycle. The primary endpoint was objective response rate (ORR) as assessed by the Response Evaluation Criteria in Solid Tumors (RECIST).<\/jats:p><\/jats:sec><jats:sec><jats:title>RESULTS.<\/jats:title><jats:p>Thirty\u2010four patients were screened for PDGFR\u03b1 and c\u2010kit expression to enroll 23 patients between December 2003 and October 2005. Four patients had c\u2010kit\u2010positive\/PDGFR\u2010negative tumors, 11 patients had PDGFR\u2010positive\/c\u2010kit\u2010negative tumors, and 8 patients had c\u2010kit\u2010positive\/PDGFR\u2010positive tumors. The median patient age was 56 years (range, 33\u201076 years). Patients had received a median of 3 prior treatments. The ORR was 21.7% and included 1 complete and 4 partial responses. An additional 3 patients had stable disease for more than 4months. Expression of PDGFR, c\u2010kit, phosphatase and tensin homolog (PTEN), and phosphorylated protein kinase B (Akt) did not predict response to therapy. The most common adverse events encountered were fatigue (83%), nausea (74%), diarrhea (61%), anorexia (52%), and edema (65%), and the majority of those events were graded as grade 1 or 2.<\/jats:p><\/jats:sec><jats:sec><jats:title>CONCLUSIONS.<\/jats:title><jats:p>The combination imatinib and docetaxel was tolerated in patients with heavily pretreated EOC that expressed c\u2010kit or PDGFR\u03b1. Few patients had sustained responses or stable disease. Cancer 2008. \u00a9 2008 American Cancer Society.<\/jats:p><\/jats:sec>","DOI":"10.1002\/cncr.23605","type":"journal-article","created":{"date-parts":[[2008,7,10]],"date-time":"2008-07-10T14:36:31Z","timestamp":1215700591000},"page":"723-732","source":"Crossref","is-referenced-by-count":68,"title":["Imatinib mesylate in combination with docetaxel for the treatment of patients with advanced, platinum\u2010resistant ovarian cancer and primary peritoneal carcinomatosis"],"prefix":"10.1002","volume":"113","author":[{"given":"Daniela","family":"Matei","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert E.","family":"Emerson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeanne","family":"Schilder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nancy","family":"Menning","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lee Ann","family":"Baldridge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cynthia S.","family":"Johnson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tim","family":"Breen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"McClean","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Doyle","family":"Stephens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles","family":"Whalen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregory","family":"Sutton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2008,7,10]]},"reference":[{"key":"e_1_2_5_2_2","doi-asserted-by":"publisher","DOI":"10.3322\/canjclin.50.1.7"},{"key":"e_1_2_5_3_2","first-page":"1502","volume-title":"Cancer: Principles and Practice of Oncology","author":"Ozols R","year":"1997"},{"key":"e_1_2_5_4_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2001.19.14.3312"},{"key":"e_1_2_5_5_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2003.10.104"},{"key":"e_1_2_5_6_2","doi-asserted-by":"publisher","DOI":"10.1126\/science.2836952"},{"key":"e_1_2_5_7_2","doi-asserted-by":"publisher","DOI":"10.1002\/j.1460-2075.1992.tb05085.x"},{"key":"e_1_2_5_8_2","doi-asserted-by":"publisher","DOI":"10.1126\/science.7701324"},{"key":"e_1_2_5_9_2","doi-asserted-by":"publisher","DOI":"10.1016\/0092-8674(84)90193-4"},{"key":"e_1_2_5_10_2","first-page":"1235","article-title":"PDGF and FGF stimulate wound healing in the genetically diabetic mouse","volume":"136","author":"Greenhalgh DG","year":"1990","journal-title":"Am J Pathol."},{"key":"e_1_2_5_11_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0304-419X(98)00015-8"},{"key":"e_1_2_5_12_2","doi-asserted-by":"publisher","DOI":"10.1006\/bbrc.2001.4622"},{"key":"e_1_2_5_13_2","doi-asserted-by":"publisher","DOI":"10.1096\/fj.02-0319com"},{"key":"e_1_2_5_14_2","doi-asserted-by":"publisher","DOI":"10.1172\/JCI200317929"},{"key":"e_1_2_5_15_2","first-page":"5476","article-title":"Inhibition of PDGF receptor signaling in tumor stroma enhances antitumor effect of chemotherapy","volume":"62","author":"Pietras K","year":"2002","journal-title":"Cancer Res."},{"key":"e_1_2_5_16_2","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-04-3991"},{"key":"e_1_2_5_17_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.onc.1205785"},{"key":"e_1_2_5_18_2","first-page":"4550","article-title":"Expression and prognostic significance of platelet\u2010derived growth factor and its receptors in epithelial ovarian neoplasms","volume":"53","author":"Henriksen R","year":"1993","journal-title":"Cancer Res."},{"key":"e_1_2_5_19_2","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.11561"},{"key":"e_1_2_5_20_2","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-0754-03"},{"key":"e_1_2_5_21_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjc.6602252"},{"key":"e_1_2_5_22_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2004.04.070"},{"key":"e_1_2_5_23_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.02.093"},{"key":"e_1_2_5_24_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.onc.1209232"},{"key":"e_1_2_5_25_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.92.7.2558"},{"key":"e_1_2_5_26_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM200104053441402"},{"key":"e_1_2_5_27_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa020461"},{"key":"e_1_2_5_28_2","doi-asserted-by":"publisher","DOI":"10.4161\/cbt.6.12.4976"},{"key":"e_1_2_5_29_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1525-1438.2007.00882.x"},{"key":"e_1_2_5_30_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2005.09.041"},{"key":"e_1_2_5_31_2","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.22757"},{"key":"e_1_2_5_32_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.07.093"},{"key":"e_1_2_5_33_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjc.6603941"},{"key":"e_1_2_5_34_2","doi-asserted-by":"publisher","DOI":"10.1053\/j.seminoncol.2004.03.037"},{"key":"e_1_2_5_35_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.89.19.9267"},{"key":"e_1_2_5_36_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1368-7646(02)00003-1"},{"key":"e_1_2_5_37_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2004.10.116"},{"key":"e_1_2_5_38_2","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/92.3.205"},{"key":"e_1_2_5_39_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2003.01.223"},{"key":"e_1_2_5_40_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjc.6603184"},{"key":"e_1_2_5_41_2","first-page":"837","article-title":"Phase II studyof docetaxel in patients with epithelial ovarian carcinoma refractory to platinum","volume":"2","author":"Kavanagh JJ","year":"1996","journal-title":"Clin Cancer Res."},{"key":"e_1_2_5_42_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.01.032"},{"key":"e_1_2_5_43_2","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0215(20000520)89:3<242::AID-IJC6>3.0.CO;2-6"},{"key":"e_1_2_5_44_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.humpath.2004.11.009"},{"key":"e_1_2_5_45_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0090-8258(02)00091-4"},{"key":"e_1_2_5_46_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2003.08.001"},{"key":"e_1_2_5_47_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2000.18.14.2733"},{"key":"e_1_2_5_48_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10147-003-0351-7"},{"key":"e_1_2_5_49_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2006.10.006"},{"key":"e_1_2_5_50_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa041318"},{"key":"e_1_2_5_51_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1997.15.1.187"},{"key":"e_1_2_5_52_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2002.09.130"},{"key":"e_1_2_5_53_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2006.05.7125"}],"container-title":["Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fcncr.23605","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/acsjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cncr.23605","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T15:38:49Z","timestamp":1760283529000},"score":1,"resource":{"primary":{"URL":"https:\/\/acsjournals.onlinelibrary.wiley.com\/doi\/10.1002\/cncr.23605"}},"subtitle":["A Hoosier Oncology Group trial"],"short-title":[],"issued":{"date-parts":[[2008,7,10]]},"references-count":52,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2008,8,15]]}},"alternative-id":["10.1002\/cncr.23605"],"URL":"https:\/\/doi.org\/10.1002\/cncr.23605","archive":["Portico"],"relation":{},"ISSN":["0008-543X","1097-0142"],"issn-type":[{"value":"0008-543X","type":"print"},{"value":"1097-0142","type":"electronic"}],"subject":[],"published":{"date-parts":[[2008,7,10]]}}}